FDA
-
-
-
-
-
-
-
FDA approves Atebrioz for rare bone-forming disease in patients 12 and up
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
-
-
-
-
-
-
-
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
-
-
-
-
-
-
-
Incyte to acquire Vega Therapeutics for $1.25 billion upfront
-
-
-
-
-
-
-
Incyte reports 24-week data for Opzelura cream in moderate atopic dermatitis
-
-
-
-
-
-
-
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
-
-
-
-
-
-
-
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
-
336,715 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


